A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
Clinical trial NCT02340221 · TERMINATED
Trial details
- NCT number
- NCT02340221
- Sponsor
- Hoffmann-La Roche
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-04-09
- Primary completion
- 2021-06-29
- Enrollment
- 631
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.